These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 34462431)
21. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295 [TBL] [Abstract][Full Text] [Related]
22. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528 [TBL] [Abstract][Full Text] [Related]
23. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997 [TBL] [Abstract][Full Text] [Related]
24. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Mullen NJ; Shukla SK; Thakur R; Kollala SS; Wang D; Chaika N; Santana JF; Miklavcic WR; LaBreck DA; Mallareddy JR; Price DH; Natarajan A; Mehla K; Sykes DB; Hollingsworth MA; Singh PK Elife; 2024 Jul; 12():. PubMed ID: 38973593 [TBL] [Abstract][Full Text] [Related]
25. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509 [TBL] [Abstract][Full Text] [Related]
26. Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells. Liu M; Xia Y; Ding J; Ye B; Zhao E; Choi JH; Alptekin A; Yan C; Dong Z; Huang S; Yang L; Cui H; Zha Y; Ding HF Cell Rep; 2016 Oct; 17(2):609-623. PubMed ID: 27705805 [TBL] [Abstract][Full Text] [Related]
27. The MYCN 5' UTR as a therapeutic target in neuroblastoma. Volegova MP; Brown LE; Banerjee U; Dries R; Sharma B; Kennedy A; Porco JA; George RE Cell Rep; 2024 May; 43(5):114134. PubMed ID: 38662542 [TBL] [Abstract][Full Text] [Related]
28. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519 [TBL] [Abstract][Full Text] [Related]
29. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells. Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892 [TBL] [Abstract][Full Text] [Related]
30. Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis. Cheung BB; Mittra R; Murray J; Wang Q; Seneviratne JA; Raipuria M; Wong IPL; Restuccia D; Gifford A; Salib A; Sutton S; Huang L; Ferdowsi PV; Tsang J; Sekyere E; Mayoh C; Luo L; Brown DL; Stow JL; Zhu S; Young RJ; Solomon BJ; Chappaz S; Kile B; Kueh A; Herold MJ; Hilton DJ; Liu T; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM Commun Biol; 2024 Oct; 7(1):1322. PubMed ID: 39402275 [TBL] [Abstract][Full Text] [Related]
31. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma. Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555 [No Abstract] [Full Text] [Related]
32. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines. Aygun N; Altungoz O Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774 [TBL] [Abstract][Full Text] [Related]
33. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression. Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217 [TBL] [Abstract][Full Text] [Related]
34. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979 [TBL] [Abstract][Full Text] [Related]
35. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma. Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM Oncogene; 2021 Apr; 40(13):2367-2381. PubMed ID: 33658627 [TBL] [Abstract][Full Text] [Related]
36. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma. He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306 [No Abstract] [Full Text] [Related]
37. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription. Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620 [TBL] [Abstract][Full Text] [Related]
38. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma. Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293 [TBL] [Abstract][Full Text] [Related]
39. Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways. Bojko J; Kollareddy M; Szemes M; Bellamy J; Poon E; Moukachar A; Legge D; Vincent EE; Jones N; Malik S; Greenhough A; Paterson A; Park JH; Gallacher K; Chesler L; Malik K Cancer Lett; 2024 Nov; 604():217263. PubMed ID: 39313128 [TBL] [Abstract][Full Text] [Related]
40. The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. Liu PY; Tee AE; Milazzo G; Hannan KM; Maag J; Mondal S; Atmadibrata B; Bartonicek N; Peng H; Ho N; Mayoh C; Ciaccio R; Sun Y; Henderson MJ; Gao J; Everaert C; Hulme AJ; Wong M; Lan Q; Cheung BB; Shi L; Wang JY; Simon T; Fischer M; Zhang XD; Marshall GM; Norris MD; Haber M; Vandesompele J; Li J; Mestdagh P; Hannan RD; Dinger ME; Perini G; Liu T Nat Commun; 2019 Nov; 10(1):5026. PubMed ID: 31690716 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]